Nasdaq:US$20.17 (-0.79) | HKEX:HK$31.70 (-1.70) | AIM:£3.24 (-0.13)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2013-04-06

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer